More on BiIB
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $216.04 |
|
|||
| Open | $218.20 | ||||
| 52 Wk High | $333.65 | ||||
| 52 Wk Low | $223.02 | ||||
| Day High | $225.59 | ||||
| Day Low | $216.97 | ||||
| P/E | 28.51 | ||||
| EPS | $7.81 | ||||
| Volume | 1,268,253 | ||||
- Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
- This biotech stock still Wolfe's top pick as multiple catalysts loomh
- Raymond James: 'We now believe that 12 of the top 20 pharma companies have selected Veeva CRM'
- Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path'
- Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
- Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
- LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
Entities mentioned with BIIB
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
